Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Where Does Genzyme See Alemtuzumab For MS? After Gilenya, Before Tysabri

This article was originally published in The Pink Sheet Daily

Executive Summary

Genzyme laid out its strategy for getting alemtuzumab to peak sales of $3.5 billion in an effort to convince investors - and Sanofi - that it's worth more money.

You may also be interested in...



Sanofi/Genzyme Primed Patient Community For Campath’s Removal From Commercial Distribution

As Sanofi/Genzyme plans to take leukemia drug Campath out of the commercial market in the U.S. and Europe so it will not undercut sales of the same compound in a different indication, patient advocates are confident that a patient-access system will continue providing the drug to those who need it.

No Homerun, But A Base Hit For Teva's Laquinimod

Teva's Phase III ALLEGRO study shows the once-daily oral multiple sclerosis candidate still has promise, but efficacy data underwhelms.

No Homerun, But A Base Hit For Teva's Laquinimod

Teva's Phase III ALLEGRO study shows the once-daily oral multiple sclerosis candidate still has promise, but efficacy data underwhelms.

Related Content

Topics

UsernamePublicRestriction

Register

PS071645

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel